Announcement on Appointment of Senior Management Members
Filed with SSE · · 2 pages · Chinese
Summary by 6ix AI
The board approved the appointment of Mr. Chen Yongjun, who meets the necessary qualifications for the role.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Earlier from Sinotherapeutics
- Announcement on Postponement of Investment Projects Financed by Raised Funds
- Announcement on Voluntary Disclosure of the Renewal and Inclusion of the Company’s Product in the National Medical Insurance Catalog
- Announcement on Attending Three-Quarter Report Collective Performance Briefing of Listed Companies in Shanghai Jurisdiction in 2025
- Report for Q3 2025
- Announcement on Voluntary Disclosure of the Proposed Selection of Products in the National Centralized Drug Procurement
Later from Sinotherapeutics
- Announcement on Voluntary Disclosure of Clinical Trial Applications for Eisaiconazole Sulfate for Injection Approved by China NMPA
- Summary Announcement on 2025 Restricted Stock Incentive Plan (Revised Draft)
- Announcement on Provision for Asset Impairment for 2025
- Announcement on Shareholding Reduction Plan for Shareholders with Over 5% Shares
- Announcement on Voluntary Disclosure of the Proposed Selection of Products in the National Continuation Drug Procurement
Follow Sinotherapeutics into a list and get an email when it puts out news.
Follow Sinotherapeutics